Last checked at 15 Jun 2021 14:19
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 14 June 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 3,657,857 5.51
| 1,068,787 1.61
| ||||
(2) Derivatives (other than options) | 521,329 0.79
|
| ||||
(3) Options and agreements to purchase/sell |
|
| ||||
Total | 4,179,186 6.30
| 1,068,787 1.61
| ||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Sale (Borrow Return)
Sale (New Loan)
Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases Purchases
Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales Sales | 11,400
367,100
105 1,244 100 9,292 1,100 14,373 1,800 200 800 1,146 100 88 1,096 251
2,219 3 7 30 228 24 9 11 423 14,373 75 12 402 18 800 4 82 202 19 9 4 65 406 | N/A
N/A
3.9400 USD 3.9300 USD 3.9200 USD 3.9127 USD 3.9100 USD 3.9074 USD 3.9056 USD 3.9000 USD 3.8925 USD 3.8809 USD 3.8800 USD 3.8700 USD 3.8684 USD 3.8600 USD
3.9300 USD 3.9233 USD 3.9214 USD 3.9202 USD 3.9200 USD 3.9181 USD 3.9178 USD 3.9136 USD 3.9100 USD 3.9074 USD 3.9067 USD 3.9033 USD 3.9000 USD 3.8967 USD 3.8925 USD 3.8900 USD 3.8857 USD 3.8800 USD 3.8700 USD 3.8689 USD 3.8650 USD 3.8642 USD 3.8600 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
Equity Swap | Decrease Long | 14,373 | 3.9075 USD |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of anyrelevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 15 June 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |